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The incidence of cardiovascular diseases is ten-times higher in males than females, although the biological basis for this gender
disparity is not known. However, based on the fact that antiplatelet drugs are the mainstay for prevention and therapy, we
hypothesized that the signaling proteomes in platelets from normal male donors might be more activated than platelets from
normal female donors. We report here that platelets from male donors express signiﬁcantly higher levels of signaling cascade
proteins than platelets from female donors. In silico connectivity analysis shows that the 24 major hubs in platelets from male
donors focus on pathways associated with megakaryocytic expansion and platelet activation. By contrast, the 11 major hubs in
platelets from female donors were found to be either negative or neutral for platelet-relevant processes. The diﬀerence may suggest
a biological mechanism for gender discrimination in cardiovascular disease.
1.Introduction
Cardiovascular diseases (CVD) are the leading causes of
deathfor men and womenin the United States, and activated
platelets have been considered central to the underlying
pathophysiology of these disorders [1–7]. For example, high
levels of intrinsically activated platelets are generally found
to circulate in patients with well-known risk factors for
many types of CVD. These include hypercholesterolemia
[8, 9] diabetes [10–12], acute ischemic stroke [13, 14],
hypertension[15,16],acutemyocardialinfarct,preeclampsia
and renal artery stenosis [17], and metabolic syndrome [18].
One practical consequence is that antiplatelet drugs, and
their individual protein receptors, have assumed center-stage
for prevention and therapy of most types of CVD.
One enduring mechanistic mystery, however, has been
the fact that the incidence and outcomes of cardiovascular
diseases are profoundly dependent upon gender [19]. Epi-
demiologically, women fare better, by approximately ten
years,thanmenintermsofageofonset,morbidity,andmor-
tality. However, considering the importance of antiplatelet
drugs for CVD, we have hypothesized that gender-speciﬁc
platelet signaling mechanisms might contribute to outcome
disparities. We have tested this hypothesis by studying the
plateletsignalingproteomeinplateletsfrommaleandfemale
donors. The donors were in the age range of 18–50, so that
the anticipated gender disparity could be directly examined.
In this paper, we report that a subset of the low-
abundance platelet signaling proteome, as assayed on quan-
titative, large-scale antibody microarrays [20, 21], is gender-
speciﬁc. Operationally, platelets from male donors express
a signiﬁcantly higher levels of proteins associated with
signal transduction and intracellular signaling cascades than
plateletsfromfemaledonors.Bycontrast,usingconventional2 Human Genomics and Proteomics
2D gel electrophoresis and mass spectrometry, we ﬁnd
that the high-abundance proteome of structural proteins
and enzymes is mostly gender-invariant. To qualify the
microarraydata,wealsoperformedsemiquantitativewestern
blot analysis on some proteins which did (or did not)
discriminate on the basis of gender. We suggest that this
discovery of the gender-speciﬁcity for the platelet signaling
proteome may contribute to understanding the biological
basis for the well-documented gender discrimination in
cardiovascular disease.
2. Methods
2.1. Platelet Preparation. Blood was donated by healthy
adult volunteers (ages 18–50) in accordance with a signed
consent form, and a human use protocol approved by
the Walter Reed Army Medical Center Institutional Review
Board. Blood was collected using a 21-gauge butterﬂy needle
into vacutainer tubes containing Acid Citrate-Dextrose as
the anticoagulant. Prostacyclin (Sigma-Aldrich, St. Louis,
MO) was immediately added to the whole blood to a ﬁnal
concentration of 50ng/mL. The prostacyclin stock solution
was 50ug/mL in 50mM Tris, 100mMNaCl, pH 12, and
stored at −80
◦C until use. Prostacyclin increases cAMP in
platelets, thus suppressing activation by inhibiting platelet
aggregation and promoting disaggregation [22]. The blood
was then centrifuged at 400×gf o r1 5m i n u t e sa t2 3
◦C
to pellet the erythrocytes and leukocytes. The platelet-rich
plasma (PRP) was then removed and prostacyclin again
added to the PRP. The PRP was then centrifuged at 1800×g
for 20 minutes at 23
◦C to pellet the platelets. The plasma
was removed and the platelets were then gently resuspended
in 2mL Tyrodes buﬀer (10mM HEPES, 0.4mMNaH2PO4,
137mMNaCl, 5.5mM glucose, 2.8mMKCl 1mMMgCl,
12mMNaHCO3). The platelets were then centrifuged a
secondtime,asbefore.Thebuﬀerwasremovedandthepellet
of puriﬁed platelets was then frozen in liquid nitrogen and
stored at −80
◦C until analyzed. Cell sorting analysis of the
ﬁnal platelet products indicated a routine purity of >99%.
2.2. Light and Electron Microscopy. Platelet-rich plasma
(PRP) was prepared as described as above, and mixed with
o n ev o l u m eo f0 . 5 Mc a c o d y l a t eb u ﬀer containing 0.5%
glutaraldehyde ﬁxative [23]. Following incubation for 30
minutes at room temperature, the platelets were centrifuged
at 800RCF for 10 minutes. The supernatant was removed
and cacodylate buﬀer containing 2.5% glutaraldehyde was
added to further ﬁx the platelets. After 10 minutes, cen-
trifugation was repeated and a fresh 2.5% glutaraldehyde
solution in cacodylate buﬀer was added. Fixed platelets were
then centrifuged as above, and the pellet processed routinely
by osmication with 2% osmium tetroxide, dehydration by
graded ethanols, and embedding in araldite. Some samples
were embedded in L.R. White medium for immuno-electron
microscopy. Occasional sections were stained with toluidine
blue and imaged by light microscopy (1000×). No evidence
of leukocyte contamination was ever observed by either light
or electron microscopy. Further details and representative
baseline data are given in Supplemental Figure 1 in supple-
mentalmaterialavailableonlineatdoi:10.4061/2010/164906.
2.3. Identiﬁcation of Proteins by 2D Gel Electrophoresis and
Mass Spectrometry. Following 2D gel electrophoresis as
previously described [24, 25], in-gel digestion of isolated
protein spots was performed as follows: protein features or
“spots” were punched with diﬀerent sized cannulae from
silver stained 2D gels (pI 4–7). The spots were selected on the
basis that their relative staining intensity revealed a gender
diﬀerence in protein abundance. Frequently, 2–4 spots were
pooled from diﬀerent gels, especially for the lower density
proteins. A protein-free gel piece and a known protein spot
were treated in parallel as negative and positive controls,
respectively. Gel pieces were processed with the Gel Digest96
Kit (Millipore, Bedford, MA). Gel pieces were destained
with 100μL of a freshly made solution of 15mM potassium
ferricyanide and 50mM sodium thiosulphate. Following
destaining, the gel pieces were dehydrated in 100μL 100%
acetonitrile. The dried gel pieces were rehydrated in 50μL
of50mMammoniumbicarbonatecontaining150ngtrypsin
(Sequencing grade, Promega, Madison,WI). After digestion
for 4 hours at 37
◦C or overnight at 30
◦C, the gel pieces were
extracted twice with 50μL of 50% acetonitrile containing
0.1% triﬂuoroacetic acid. The combined extraction solution
was concentrated to 5μL in a SpeedVac.
For peptide mass ﬁngerprinting by mass spectrometry,
the peptide mixture was puriﬁed with an in-tip reversed-
phase column (C18 Zip-Tip; Millipore Corp., Bedford, MA)
to remove salts and impurities. Routinely, peptides were
analyzed by MALDI-TOF technology, as follows: the peptide
mixture was mixed with 1μLo fm a tri xs o l u t i o n( 8m g / m Lα-
cyano-4-hydroxycinnamic acid in 50% ACN/0.1%TFA) and
spotted onto a MALDI target plate. Analysis was performed
using a MALDI-TOF mass spectrometer (Voyager DE-STR;
Applied Biosystems, Framingham, MA) equipped with a
337nm nitrogen laser. Samples were analyzed in reﬂectron
mode by time-of-ﬂight at an accelerating potential 20KV.
Mass spectra were recorded and then processed using the
AppliedBiosystemsDataExplorerVersion4.0.0.0softwareto
include: calibration using external standards of bradykinin
(monoisotopic (M + H value = 1060.56) and adrenocorti-
cotropic hormone (ACTH), clip 18–39 (monoisotopic (M +
H) value = 2465.20), baseline correction, noise ﬁltering
(correlation factor 0.7), deisotoping, setting of baseline
intensity (peaks intensities >3 times background), and peak
gathering. Lists of monoisotopic peptide mass ions were
then submitted to ProteinPropector MS-Fit (version 4.27.2
basic; http://prospector.ucsf.edu/) for searching against the
current versions of the Swiss Prot (20071010) and NCBInr
(20071010) data bases. Allowed mass tolerance was set a
50ppm, or less. Unmatched peptides, amino acid modiﬁca-
tions, or peptides with missed cleavages were not considered.
Additional components contributing to an identiﬁcation
included: (i) visual inspection of all spectra to ensure that
peptide ions contributing to a protein identiﬁcation had an
appropriatesignal-to-noiseratio(>3 : 1)andatleastone 13C
isotopic form and (ii) performance of separate conﬁrmatoryHuman Genomics and Proteomics 3
experiments using independent samples (n = up to 3).
While in some cases a MOWSE score for a given protein
identiﬁcation was low, the identifying peptide ions were
readily detected and consistently observed in conﬁrmatory
experiments.
2.4. Bioinformatics for Analysis of 2DGE Data. 2DGE data
were analyzed by ProGenesis software (Nonlinear USA,
Durham, NC.), as previously described [24, 25]. Brieﬂy, the
software identiﬁed equivalent spots on gels for platelets from
all 16 donors. Each spot on each gel was then normalized
to the total spot density on that gel, and the densities of
each spot corrected by ﬁtting all spots to a log-normal
distribution. All data for each spot on all male and all female
platelet gels, respectively, were then averaged and the two
datasets were compared for signiﬁcant diﬀerence by t-test.
Further analytic details are as described [24, 25].
2.5. Fluorescent Labeling of Platelet Proteins. Platelet proteins
were labeled reciprocally with either Cy3 or Cy5 on the basis
of “per mg of protein”, as described [20]. Labeled proteins
were separated on a PD10 column to remove unreacted dyes.
Equal volumes of labeled platelet proteins were mixed for
multiplex analysis on the microarrays. In each case, a platelet
sample from a male donor was compared with a platelet
sample from a female donor. Dye swapping was performed
in order to label each platelet sample with both Cy3 and Cy5,
and to correct for labeling eﬃciency of each dye. Following
incubation, and washing, the dried slides were imaged on
a GenePix 4000B (Axon Instruments) ﬂuorescence scanner.
The data were then exported oﬀ line for analysis.
2.6. Antibody Microarrays. The antibody microarrays used
in these experiments were obtained from Clontech (Moun-
tain View, CA), and were printed according to our qual-
ity control speciﬁcations. The list of antibodies used in
the microarray is available on the Clontech(R) website:
http://bioinfo.clontech.com/abinfo/initialize.do#, using Cat-
alog no. 631790 and Lot no. 5100723. The arrays were
otherwise handled exactly as recommended by the manufac-
turer. Each microarray has exactly 507 features, printed in
duplicate. However, over the course of this experiment, two
lots were employed in which a few antibodies were replaced
with others. The result was that we were able to analyze a
totalof573individualproteinsinall16plateletpreparations.
In conclusion, each protein on each array, as provided
by platelets from individual donor, was interrogated 8
independent times, with 24 replicate measurements.
2.7. Bioinformatics for Analysis of Antibody Microarrays.
Antibody microarrays were analyzed as described [20, 21].
Brieﬂy, each array was exposed to platelets from male
and female donors, where one gender was labeled with
Cy3 and the other with Cy5. A second array was run in
parallel in which the labels switched to either Cy5 or Cy3,
respectively. The data were then averaged to yield gender-
speciﬁc diﬀerences. Traditionally, this strategy corrects for
the possibility of diﬀerent proteins being labeled selectively
byeitherdye.Thereafter,(i)afterthestepsofsampleprocess-
ing, ﬂuorescent labeling of proteins, and binding to antibody
microarrays, images were read and the intensity values for
each array location were tabulated in silico. (ii) Data for
each array were normalized by dividing by the median of
the values for the speciﬁc array and speciﬁc wavelength. (iii)
Signiﬁcance analysis (t-test) was used to determine whether
as p e c i ﬁ cp r o t e i nw a sd i ﬀerentially expressed in the male
platelets versus female platelets. This analysis resulted in
a “top candidate” list for further validation. To compare
the absolute levels, we calculated the absolute protein level
ratios using the manufacturer’s protocol (the “square-root”
method). These ratios were tightly scattered around the
average ratio R = 1.4, with a coeﬃcient of variation (CoV)
of ∼13% (SEM/R = 7%). We then used this value of R as an
estimate of the ratio of medians of the two samples.
In addition, we calculated for each protein, using the
respective averages and SDs, the sample size needed to
determine at 80% power if there were a signiﬁcant dif-
ference between the groups. Wilcoxon Rank Order Non-
Parametric Methods were subsequently employed for iden-
tifying the candidate proteomic signature. (iv) The Signiﬁ-
cance Analysis of Microarrays algorithm application (SAM,
[26] http://www.stat.stanford.edu/∼tibs/SAM;) was used for
calculating False Discovery Rates (FDR), and to estimate
the Local False Discovery Rate for each of the proteins.
A Local False Discover Rate of <10% was taken as a
cutoﬀ of signiﬁcance; (v) Cluster analysis with hierarchical
cluster analysis software (http://rana.lbl.gov/eisen/software)
was used to ﬁnd groupings of “similar expression” for both
proteins and genders [27, 28]. (vi) Network analysis of direct
interactions and associated tables of network statistics were
created with Metacore Version 4.7 (GeneGo, St. Joseph, MI)
from gender-speciﬁc lists of proteins. The direct interaction
algorithm creates a network only from the objects in the
original list using curated links in the database. The tables of
network statistics are based upon the objects displayed in the
network. A hub is deﬁned as an object with 5 or more links
on the network; objects with fewer connections are nodes.
Finally, (vii) classical ROC (Receiver Operating Charac-
teristic) curves, were calculated, and respective AUC’s (Area
under the curve) were calculated for each protein in the two
cohorts. An AUC equal to 1 shows complete separation of
the distributions in the two cohorts. Thus, all the values in
one cohort are above the cutoﬀ, while all the values in the
secondcohortarebelowthatcutoﬀ.InordertoplottheROC
curves we assumed that the measured replicates for each
individual were normally distributed around the respective
true level, of the given protein, with a width estimated by the
standard deviation of the measured replicas. Thus, for each
cutoﬀ level the % false Positives and % False Negatives were
calculatedbyintegratingthetailofthenormaldistributionin
the respective direction. This approach actually estimates the
chance of measuring aFalsePositive(orFalseNegative)given
the average and SD of the measurement for that given cutoﬀ.
The AUC values were then calculated by integrating the ROC
curve. Further information and a summary of results are
given in Supplemental Table 10. ROC graphs are shown in
Supplemental Figure 4.4 Human Genomics and Proteomics
2.8. Western Blot Analysis. These assays were performed by
standard methods, using chemiluminescence detection. For
data in Figure 3, individual platelet samples were assayed,
and averages and SEM’s calculated in silico.
3. Results
3.1. Prostacyclin Treatment of Blood Sample Prevents Platelet
Activation. Platelets are known to secrete large numbers
of internal proteins when they are activated. Therefore,
to ensure that the platelets chosen for proteomic analysis
were maintained in an unactivated state, we routinely added
prostacyclin (50nM) to the blood samples within seconds
after collection (see Methods). Supplemental Figure 1 shows
representative optical and electron microscopy data for male
and female platelets. At the light microscopy level, platelets
from male donors (Supplemental Figure 1b)a n df e m a l e
donors (Supplemental Figure 1d) appear as classically resting
“face-on” ﬂat discoids or “edge-on” fusiform structures.
At the electron microscopic level, both the platelets from
male donors (Supplemental Figure 1a) and female donors
(Supplemental Figure 1c) are shown in the “face-on” view
as smoothly spherical bodies with uniformly distributed
internal subcellular organelles. During the course of this
study, platelet preparations were randomly checked by
this direct measure of activation. As anticipated, platelets
prepared without added prostacyclin were often charac-
terized by acanthocytic membrane protroberances, large-
scale aggregation, centralization of organelles, and massively
dilated internal canalicular systems.
3.2.ASmallFractionoftheHigh-AbundancePlateletProteome
Is Gender-Dependent. As shown in Supplemental Figure 2,
discovery studies with 2D-Gel Electrophoresis (2DGE) and
mass spectrometry revealed at least 2800 silver-stained
proteins. Of the detectable proteins, only 20 (or ca.0 . 7 %
of the total) had relative expressions that were signiﬁcantly
gender-speciﬁc. The fold diﬀerences and P-values for sig-
niﬁcance are summarized in Supplemental Table 1. Of the
20 candidate features, only 12 could be detected by eye.
We therefore punched only these 12 for identiﬁcation by
mass spectrometry. However, of these 12, only six yielded
signiﬁcant identiﬁcations. Two of these spots (no. 1101 and
no. 1583) had two signiﬁcantly identiﬁable proteins. Thus,
we were able to identify eight proteins in total from the 2D
gels. These eight proteins are listed in Supplemental Table 2.
Relevantly, one of these proteins, GNA11, is a G-q class G-
protein associated with response to thrombopoeitin (TPO).
These data indicate that most high abundance proteins
in human platelets occur in equivalent amounts in both
male and female donors. However, the few high abundance
proteins that do discriminate on the basis of gender seem to
be at the limit of conventional detection and identiﬁcation.
3.3. Low-Abundance Signaling Proteins in Platelets Can Be
Identiﬁed Using an Antibody Microarray Platform. As shown
in Figure 1, low-abundance platelet proteins from male or
female donors, undetectable on the 2D gel platform and
Figure 1: Platelet proteins from male and female donors analyzed
on an antibody microarray platform. Equal amounts of platelet
proteins were labeled with either Cy3 or Cy5, and incubated with
the antibody microarray as described in the Methods section. Net
green or net red spots indicate diﬀerences according to gender.
Yellow spots indicate equivalent amounts of bound antigen.
labeled with either Cy3 or Cy5, can be multiplexed for
quantitative analysis on the microarray platform. We noted
that of 576 informative proteins, 442 (ca. 75%) proteins had
standard errors of the mean (SEM) of 20% or less, while
the remaining 25% had sharply divergent values. These data
are shown in Supplemental Figure 3, in which the analysis
of variance was calculated for the ﬁrst set of eight patients
(Supplemental Figure 3a), and then for the aggregate of the
ﬁrst eight and the second eight sets of patients (Supplemental
Figure 3b). There is virtually no diﬀerence, in spite of a two-
month separation in the collection and analysis of the two
sets of platelet samples. We also noted a close correlation
of SEM’s for individual proteins when comparing male and
female samples. For the subsequent bioinformatics analyses,
we therefore decided to concentrate our attention on the ca.
75% of the proteins in the low SEM class. As for the group
of proteins with the highest SEM’s, we concluded that this
group might just reﬂect idiosyncratic diﬀerences among the
donors.
3.4. Relative Rank Order Analysis of Low-Abundance Pro-
teome Distinguishes and Identiﬁes Proteins That Are Most
Diﬀerentially Expressed by Gender. Figure 2 shows a series
of graphical comparisons between low-abundance platelet
proteomes from male and female donors. Figure 2(a) com-
pares the average rank order for all eight males with the
average individual rank orders by gender. The data indicate
that the proteins expressed by platelets individually from all
eight males are very similar to their aggregate male averages.
Figure 2(b) performs the same individual comparison for all
eight female donors with the average individual rank orders
by gender. The data indicate that the proteins expressed
by platelets from all eight female donors are very similar
to their aggregate female average. However, the rank order
for protein expression in platelets from female donors is
poorly correlated with male expression levels. Thus the low-
abundance platelet proteome, as deﬁned by the antibody
microarray, is strongly gender-speciﬁc.Human Genomics and Proteomics 5
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Figure 2: Antibody microarray analysis of platelets from normal adult male and female donors. (a) Average rank by gender versus average of
all males. Blue circles are proteins from male donors. Red circles are proteins from female donors. (b) Average rank by gender versus average
of all females. Blue circles are proteins from male donors. Red circles are proteins from female donors.
We further increased the statistical stringency of our
gender-speciﬁc discrimination using the Statistical Analysis
of Microarrays (SAM) algorithm (20). The conditions we
imposed on the SAM calculations included 2000 permu-
tations, a local False Discovery Rate (FDR) <10%, and a
q-statistic <0.05. Of 573 total proteins analyzed, 161 (viz,
28%) were found to satisfy this degree of stringency. Table 1
shows the top 15 proteins in this highly stringent and
signiﬁcant gender diﬀerence. These proteins are ranked by
t-test, starting with c-MYC. In this instance, the t-test is
3.5 × 10
−20. The far right-hand columns in Table 1 show
that c-MYC ranks ca. 91% in females versus only ca. 25% in
males. The entire dataset is shown in Supplemental Table 3,
and is arbitrarily truncated when the “Δ Rank” value reaches
20%. Thus even with the most stringent statistical criteria
available, the low-abundance signaling proteome in platelets
can be distinguished on the basis of gender.
3.5. Gender-Speciﬁc Rank Order Analysis Can Distinguish
Proteomic Signatures in Platelets. Table 2 shows the top 15
proteins present in platelets from male donors which are also
in the list of proteins diﬀerentially expressed as a function
of gender. In this case we have included a few proteins for
which the local FDR is slightly more than 10%. For example,
the highest ranked protein in males is general transcription
factor II,I (GTF2I), ranked at ca. 96.5%. This compares with
only ca. 44.8% in platelets from female donors. Second on
the list is Mdm2 (MDM2), a p53 binding protein. The third
isphospholipaseC,beta1(PLCB1),whichisrankedca.94%.
Bycontrast,PLCB1isonlyrankedca.26%infemaleplatelets.
The entire list of 76 proteins is summarized in Supplemental
Table 4. Many of the proteins on this male-speciﬁc list are
closely associated with either megakaryocyte expansion or
platelet activation, and will be discussed further in the
context of a systems-biology-based analysis (see Table 4).
Table 3 shows an equivalent relationship for the top
15 proteins in female platelets. The top protein in Table 3
is the tumor suppressor gene p53, closely followed by
protein kinase C epsilon (PRKCE), multiple PDZ domain
protein (MPDZ), and nuclear factor of activated T-cells 2
(NFATC2). The entire list of 91 proteins is summarized
in Supplemental Table 5. These are familiar and interesting
proteins in their own right. However, a more comprehensive
systems approach, as explored below, will be necessary to
understand this proteome in terms of platelet function.
Nonetheless, the only point to be made by these tables alone
isthattherelativeexpressionofproteinsinvolvedindisparate
signaling processes is profoundly diﬀerent in platelets from
male and female donors.
3.6. Antibody Microarray Data Can Be Qualiﬁed by Com-
p a r i s o nw i t hW e s t e r nB l o tA n a l y s e s .To qualify the antibody6 Human Genomics and Proteomics
Table 1: Top 15 low-abundance proteins with highly stringent signiﬁcant diﬀerences on the basis of gender.
ID t-test Gen code HUGO RANK
Females Males Delta
v-myc myelocytomatosis viral oncogene homolog avian 3E −20 −1M Y C 9 1 ±2% 25 ±2% 66%
Ras-related C3 botulinum toxin substrate 1 rho family,
small GTP binding protein Rac1
8E −15 1 RAC1 37 ±2% 83 ±3% 46%
polymerase DNA directed, epsilon 1E −14 −1 DPOE1 60 ±1% 14 ±1% 47%
proteasome prosome, macropain 26S subunit, ATPase, 5 2E −14 −1 PSMC5 90 ±2% 27 ±1% 63%
synapsin II 3E −14 −1S Y N 2 9 4 ±1% 34 ±2% 60%
synaptotagmin I 4E −14 −1S Y T 1 8 8 ±1% 33 ±2% 55%
A kinase PRKA anchor protein yotiao 9 2E −13 1 AKAP9 41 ±3% 86 ±3% 45%
phosphatidylinositol 4-kinase, catalytic, beta
polypeptide
1E −12 −1P I K 4 C B 8 6 ±1% 38 ±2% 48%
protein tyrosine phosphatase, non-receptor type 11
Noonan syndrome 1
3E −12 −1 PTPN11 82 ±3% 28 ±1% 55%
A kinase PRKA anchor protein gravin 12 5E −11 1 AKAP12 32 ±1% 83 ±3% 52%
RAB5A, member RAS oncogene family 1E −10 −1 RAB5A 86 ±2% 59 ±2% 27%
lymphocyte cytosolic protein 2 SH2 domain containing
leukocyte protein of 76kDa
1E −10 −1L C P 2 7 9 ±4% 38 ±4% 41%
amphiphysin Stiﬀ-Man syndrome with breast cancer
128kDa autoantigen
1E −09 −1A M P H 8 9 ±4% 48 ±4% 41%
TRAF family member-associated NFκBa c t i v a t o r 2E −09 −1T A N K 5 5 ±2% 36 ±2% 18%
solute carrier family 9 sodium/hydrogen exchanger,
isoform 3 regulatory factor 1
4E −09 1 NHERF-1 32 ±2% 75 ±5% 43%
leukocyte-associated Ig-like receptor 1 5E −09 −1 LAIR1 60 ±2% 40 ±2% 20%
 (−1) = female; (+1) = male
microarray ﬁndings, we tested a subset of the proteins with
ar a n g eo fd i ﬀerential expressions using the semiquanti-
tative western blot technology. Figure 3(a) shows average
western blot data from three independent experiments with
antibodies against 9 diﬀerent proteins: Caspase 7, IκBα,
STAT3,PKCα,PK Cβ,MAPK1,PK Cδ,ERK(MAPK3),andβ-
integrin. From the bar graph, it is evident that some proteins
diﬀer quite a lot (e.g., STAT3) while others are almost equally
expressed (e.g., PKCδ). Figure 3(b) tests for a correlation
between the intensities of these proteins on the antibody
microarray (Supplementary Tables 4 and 5) and the western
blot data. We ﬁnd that there is a correlation that is evident
by inspection. In addition, with the R2 values of this plot
ranging in diﬀerent experiments from 0.85 to 0.94, it appears
that the slope of the western versus spot intensity plot is not
statistically diﬀerent from 1. We conclude that the gender-
based diﬀerences, as deﬁned by the antibody microarray
analysis, can be qualiﬁed by Western blot for a limited range
of identiﬁed signaling proteins.
4. Discussion
In this paper, we report that the low-abundance platelet
signaling proteome is profoundly gender-speciﬁc. These
gender-speciﬁcdiﬀerencesinproteinexpressionwerediscov-
ered using novel, large-scale antibody microarrays. Highly
stringent statistical analyses, using the SAM algorithm for
calculating local False Discovery Rates (FDR), identify 76
of 576 candidate low-abundance proteins that were more
highly expressed in male platelets, and 91 proteins among
the same candidates that were more highly expressed in
female platelets. We also qualiﬁed expression levels of nine
of the proteins by a standard Western blot method. By
contrast, using conventional 2D Gel Electrophoresis and
mass spectrometry, we detected and identiﬁed only a few
gender-speciﬁc diﬀerences in the set of ca. 2800 high
abundance structural and metabolic proteins. Finally, using
in silico connectivity analyses of the low-abundance platelet
proteomes,weﬁndthatplateletsfrommaledonorshavehigh
connectivity hubs that are more heavily weighted towards
megakaryocyte expansion and platelet activation processes
than platelets from female donors. Based on these data,
we suggest that this discovery of the novel gender-speciﬁc
plateletsignalingproteomemaycontributetounderstanding
biological basis for the well-documented female gender
advantage in cardiovascular disease.
4.1. Connectivity Analysis Yields Candidate Functional Infor-
mation on Gender-Based Platelet Proteomics. Connectivity
analysis is an important analytic technique that can be
used to identify candidate regulatory mechanisms that
are implicit in proteomic and genomic data. Data from
SupplementaryTables 4and5were therefore used to generate
connectivity plots for [male > female] data (Figure 4(a))a n d
[female > male] data (Figure 4(b)), respectively. Both graphs
show that relatively few proteins form hubs that connectHuman Genomics and Proteomics 7
Table 2: Top 15 low-abundance proteins that are expressed in platelets from male donors.
ID Rank in females Rank in males Delta rank local FDR Symbol
general transcription factor II, i (44.8 ±3.7)% (96.5 ±1.0)% ↓ 51.7% 13% GTF2I
Mdm2, transformed 3T3 cell double minute 2, p53
binding protein (mouse)
(78.2 ±4.0)% (94.9 ±1.3)% ↓ 16.7% 0% MDM2
phospholipase C, beta 1 (phosphoinositide-speciﬁc) (26.0 ±1.9)% (93.9 ±1.1)% ↓ 67.9% 13% PLCB1
sortilin-related receptor, L(DLR class) A
repeats-containing
(74.4 ±2.3)% (93.6 ±1.5)% ↓ 19.3% 0% SORL1
ras homolog gene family, member A (75.1 ±2.6)% (93.5 ±1.5)% ↓ 18.4% 0% RHOA
colony stimulating factor 1 receptor, formerly
McDonough feline sarcoma viral (v-fms) oncogene
homolog
(52.1 ±7.9)% (92.9 ±1.0)% ↓ 40.8% 0% CSF1R
homer homolog 1 (Drosophila) (77.9 ±2.4)% (92.2 ±0.9)% ↓ 14.3% 0% HOMER1
FK506 binding protein 10, 65kDa (56.2 ±5.3)% (90.7 ±2.0)% ↓ 34.5% 0% FKBP10
phosphoinositide-3-kinase, regulatory subunit,
polypeptide 1 (p85 alpha)
(53.9 ±2.4)% (90.4 ±2.0)% ↓ 36.5% 12% PIK3R1
caveolin 1, caveolae protein, 22kDa (59.6 ±4.5)% (89.0 ±0.9)% ↓ 29.5% 12% CAV1
proliferating cell nuclear antigen (69.6 ±3.4)% (88.8 ±2.1)% ↓ 19.2% 0% PCNA
contactin 1 (57.3 ±3.5)% (88.6 ±2.7)% ↓ 31.4% 6% CNTN1
mitogen-activated protein kinase 3 (71.5 ±3.9)% (87.7 ±2.0)% ↓ 16.2% 6% MAPK3
ubiquitin fusion degradation 1-like (53.2 ±4.4)% (87.6 ±1.7)% ↓ 34.4% 10% UFD1L
by edges to many other identiﬁed proteins. However, as
summarized in Tables 4(a) and 4(b), gender makes quite a
diﬀerence in terms of the functional identities of the high-
est occupancy hubs. The diﬀerences extend to diﬀerential
levels of transcription factors (Supplemental Table 6)a n d
membrane receptors (Supplemental Table 7). Furthermore,
as shown in Supplementary Table 8, these diﬀerences fall into
fundamentally diﬀerent functional categories when viewed
from the perspective of gene ontology (GO) categories.
Among the top 5 GO categories for platelets of male origin
are signal transduction and intracellular signaling cascade,
all with high percentage and P values <10−15. By contrast,
the top 5GO categories for platelets of female origin contain
neither of these categories, and the category with highest P
value,“positiveregulationofcellularprocesses”,isonly10−13.
Finally, as discussed below, the set of male hubs in Table 4(a)
is generally more closely associated with platelet activation
processes than are the female hubs in Table 4(b).
4.2. Highly Connected Protein Hubs in Male Platelets Support
Megakarycytic Expansion and Platelet Activation Processes.
The 24 most highly connected hubs in the male platelet pro-
teome are summarized in Table 4(a). The data are ordered
in terms of numbers of edges per hub. The assumption in
this analysis is that functional importance may be related to
the most highly connected hubs. However, the interactions
database is constructed from all biological systems. We
therefore needed to query the literature for the relevance of
each hub to platelets and precursor megakaryocytes. We ﬁnd
that these male-speciﬁc hubs fall mainly into two categories:
thrombopoeitin (TPO)-driven megakaryocyte development
and platelet activation. Twelve of the 24 male-speciﬁc hubs
are directly associated in the literature with megakaryocytic
development and expansion. For example, (no. 1) STAT3 is
activated by TPO [29], leading to expansion of megakary-
ocytic progenitor cells [30], and a parallel increase in platelet
mitochondrial transcription [31]. Other hubs documented
for megakaryocytic expansion activities include (no. 2) c-
FOS, [32]; (no. 3) CBP (CREB Binding Protein, [33]; (no.
5) Cyclin D1 [34]; (no. 7) c-Raf-1 [35]; (no. 9) CDK1/p34
[36, 37]; (no. 11) HDAC3 [38]; (no. 12) JNK1/MAPK8
[39]; (no. 16) PU.1/PBP [40]; only found in platelets or
megakaryocytes) and (no. 19) PI3K Reg Class 1A/p85alpha
[41]. Three other male-speciﬁc hubs are directly associated
with STAT 3 regulation in platelets. These include (no. 15)
PDGF-R-beta [42], (no. 18) Interleukin 6IL-6 [43, 44], and
(no. 21) CRM1 [45]. CRM1 mediates shuttling of activated
STAT3inandoutofthemegakaryocytenucleus.Thusatleast
54% (13 of 24) of the male-speciﬁc hubs are associated with
the megakaryocytic expansion process. We interpret their
presence in mature platelet to represent an archeological
remnant of events occurring in the precursor megakaryocyte
compartment.
Nine of these 24 male-speciﬁc hubs have well-chara-
cterized relationships to intrinsic platelet activation pro-
cesses. (no.4) RhoGTPaseRAC1 is activated by α-thrombin
touncapactinﬁlamentsanddrivetheprocessofcytoskeleton
remodeling in stimulated platelets [46, 47]. (no. 6) beta-
catenin is present in platelets [48], and interacts with cad-
herinsonendothelialcells[49].Thisinteractionmediatesthe
process of adherence between platelets and endothelial cells,
which must occur during blood coagulation. (no. 8) ERK1
(MAPK3) is obligatorily phosphorylated when thrombin
activates platelets [47]. Pharmacologically, davallialactone8 Human Genomics and Proteomics
Table 3: Top 15 low-abundance proteins that are expressed in platelets from female donors.
ID Rank in females Rank in males Delta rank local FDR Symbol
tumor protein p53 binding protein, 2 (96.4 ±0.5)% (19.0 ±0.6)% ↑ 77.4% 10% TP53BP2
protein kinase C, epsilon (96.3 ±1.0)% (53.9 ±2.9)% ↑ 42.3% 15% PRKCE
multiple PDZ domain protein (94.8 ±0.7)% (17.5 ±1.6)% ↑ 77.3% 15% MPDZ
nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 2
(94.7 ±0.9)% (58.5 ±2.7)% ↑ 36.2% 15% NFATC2
synapsin II (94.0 ±0.7)% (33.9 ±2.0)% ↑ 60.2% 0% SYN2
cell division cycle 27 (93.8 ±1.3)% (61.2 ±6.7)% ↑ 32.6% 0% CDC27
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 (93.4 ±1.8)% (58.4 ±5.4)% ↑ 34.9% 0% DDX1
scavenger receptor class B, member 1 (93.0 ±1.6)% (42.0 ±7.3)% ↑ 50.9% 0% SCARB1
centrosomal protein 2 (92.1 ±2.1)% (62.6 ±5.0)% ↑ 29.5% 0% CEP2
neuropilin 2 (91.9 ±1.7)% (59.4 ±5.6)% ↑ 32.5% 0% NRP2
tumor protein p53 (Li-Fraumeni syndrome) (91.2 ±2.5)% (23.8 ±1.9)% ↑ 67.4% 15% TP53
SV40 Large T Antigen (91.0 ±0.6)% (68.0 ±3.0)% ↑ 23.0% 12% —
v-myc myelocytomatosis viral oncogene homolog
(avian)
(90.6 ±2.4)% (24.9 ±1.9)% ↑ 65.7% 0% MYC
proteasome (prosome, macropain) 26S subunit,
ATPase, 5
(89.8 ±1.9)% (26.8 ±1.0)% ↑ 63.0% 0% PSMC5
amphiphysin (Stiﬀ-Man syndrome with breast cancer
128kDa autoantigen)
(89.3 ±3.6)% (48.2 ±4.1)% ↑ 41.1% 0% AMPH
[50] and the antiseizure drug gabapentin [51] inhibit
collagen or ADP-activated platelet activation by blocking
p38 MAPK phosphorylation. (no.13) PKC-beta-1 is a nega-
tive regulator of thrombin-receptor-mediated calcium entry
[52]. (no. 14) RACK1 regulates platelet-speciﬁc outside-in
signaling by the following process: [ﬁbrinogen >Integrin
alpha2b, beta 3 >RACK1 >PKCbeta-1] [53]. (no. 18) IL-6,
in addition to interacting directly with STAT3 (see above),
also makes mature platelets more sensitive to activation
by thrombin and platelet activating factor [43]. (no. 19)
PI3K Reg Class 1A/p85 alpha, in addition to mediating
megakaryocytic expansion, enhances thrombin-dependent
alpha granule secretion in platelets [54]. (no. 23) PKC-
beta 2 and a splice variant, PKC-beta 1, are activated in
thrombin-stimulated platelets [55]. (no. 24) PLC-gamma-
1 is phosphorylated following platelet activation and con-
tributes both calcium and diacylglycerol to activate protein
kinase C isoforms [56]. Thus at least 38% (9 of 24) of the
male-speciﬁc hubs are associated with processes that drive
platelet activation.
The remaining four male-speciﬁc hubs do not have
speciﬁc functional relationships to platelet biology. One of
theseis(no.10)Caspase7,whichwealsoqualiﬁedasgender-
speciﬁc by western blot analysis (see Figure 3). Furthermore,
apoptotic processes in megakaryocytes are known to be
involved in the genesis of platelets [57–59]. However, why
this hub should be enhanced in a gender-speciﬁc manner
in mature platelets is not yet apparent. (no. 17) CRK, the
human homolog of the avian sarcoma virus oncogene, has
no association in the literature with the platelet system.
(no. 20) TFII-I has both nuclear and cytoplasmic functions,
but none yet are documented for the platelet system [60].
Finally, (no. 22) NCOA3 (pCIP/SRC3) is associated by an
unknown mechanism with a decrease in circulating platelets
in Src3(−/−) knockout mice [61].
4.3. Highly Connected Proteins Hubs in Female Platelets Are
EitherNegativeorNeutralforPlatelet-RelevantProcesses. The
eleven most highly connected hubs in the female platelet
proteome are summarized in Table 4(b). The top three
hubs in this set are associated with processes that tend to
suppress megakaryocytic expansion processes. For example,
(no. 1) c-MYC is a transcription factor whose expression
is induced in megakaryocytes by thrombopoeitin. Alone,
thrombopoeitin is a trophic factor which promotes survival,
proliferation, and polyploidization of megakaryocytes [41].
However, concommitant c-MYC elevation actually has the
consequence of reducing megakaryocytopoiesis, and decreas-
ing polyploidization [62]. Thus there are minimal eﬀects
on circulating platelet levels. cMYC binds to and induces
expression of (no. 6) p73, and both together downregulate
PDGF beta receptors [63]. (no. 11) MAX binds to c-MYC,
but there is no platelet or megakaryocyte-speciﬁc literature
regarding function. (no. 2) p53 is the tumor suppressor
gene p53. Elevation of p53 in a megakaryocyte cell line acts
to reduce polyploidization, and to impede the transition to
endomitosis. p53 achieves these megakaryocytic endpoints
by suppressing cell cycling and by promoting apoptosis
[64]. (no. 3) GCRA is the glucocorticoid receptor-alpha.
Functional glucocorticoid receptors have been previously
identiﬁed in a human megakaryocytic cell line, where
agonists reduced cell growth and diﬀerentiation [65]. The
glucocorticoid dexamethasone has also been shown to coun-
teract the eﬀect of chronic idiopathic thrombopenia purpuraHuman Genomics and Proteomics 9
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Figure 3: Qualiﬁcation of quantitative Antibody Microarray data
with semiquantitative Western blot analysis of selected proteins in
platelets from male and female donors. (a) Western blot analysis
of selected proteins in platelets from male and female donors. Each
sampleistheaverageof3–5independentdeterminations(∗P ≤ .05,
∗∗P ≤ .02 and ∗∗∗P ≤ .001). (b) Correlation between Western blot
data in  a  and cognate antibody microarray intensities.
(ITP)onmegakaryocytopoiesisandplateletproduction[66].
(no. 4) Lck is the lymphocyte-speciﬁc tyrosine kinase (Lck),
which in spite of its name, is a Src-family kinase that is also
found in platelets [67]. However, unlike the close association
of other members of the Src family with platelet activation,
the function of Lyk in platelets is unknown. Thus unlike the
caseforthetoprankedmale-speciﬁchubs,6ofthe11thetop
ranked female hubs are distinctly either negative or neutral
with respect to either megakaryocte expansion or platelet
activation processes.
Table 4: Connectivity analysis of the gender-dependent platelet
signaling proteome. (a) Summary of top 24 hubs in male platelets
in terms of edges connecting the hub protein to other proteins.
(b) Summary of top 11 hubs in female platelets in terms of edges
connecting the hub protein to other proteins.
(a) Hubs with increased expression in male platelets.
No. Name Edges
1S T A T 3 1 9
2c - F o s 1 5
3C B P 1 5
4R a c 1 1 2
5C v c l i n D 1 1 1
6 Beta-catenin 10
7 c-Raf-1 10
8 ERK1 (MAPK3) 10
9 CDK1 (p34) 9
10 Caspase-7 8
11 HDAC3 8
12 JNK1(MAPK8) 8
13 PKC-beta 8
14 RACK1 8
15 PDGF-R-beta 7
16 PU.1 7
17 CRK 6
18 IL-6 6
19 PI3K reg class IA (p85-alpha) 6
20 TFII-I 6
21 CRM1 5
22 NCOA3 (pCIP/SRC3) 5
23 PKC-beta2 5
24 PLC-qamma 1 5
(b) Hubs with increased expression in female platelets.
No. Name Edges
1c - M y c 4 1
2 p53 24
3G C R - a l p h a1 3
4L c k 1 2
5 PKC-alpha 9
6p 7 3 8
7S H P - 2 8
8S H P - 1 7
9G S K 3 b e t a 6
10 IKK-alpha 5
11 Max 5
However, there are several lower ranked female-speciﬁc
hubs that are either negative or possibly neutral for platelet
activation. (no. 7) SHP-2 is a tyrosine phosphatase which
binds to PECAM-1 [68] during the thrombin-induced
platelet aggregation process [69]. (no. 8) SHP-1 is a splice10 Human Genomics and Proteomics
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Figure 4: Connectivity analysis of gender-speciﬁc signaling proteins in platelets from male and female donors. (a) Connectivity analysis of
platelet signaling proteins that are ranked higher in male than female donors. (b) Connectivity analysis of platelet signaling proteins that are
ranked higher in female than male donors.Human Genomics and Proteomics 11
variantofSHP-2,whichbindswithlesseraﬃnitytoPECAM-
1 during platelet aggregation [70]. Although both SHP-
1 and SHP-2 are said to be positive regulators of signal
transduction, their speciﬁc functions in platelets are not
yet known. (no. 9) GSK3beta has inhibitory actions on
platelet aggregation processes. For example, platelets from
aG S K 3 b e t a( + / −) mouse demonstrate enhanced agonist-
dependent aggregation, as do human platelets treated with
GSK3beta inhibitors [71]. Finally, (no. 10) IKKalpha is a
key regulator of proinﬂammatory NFκB activation, which
regulates this process in human platelets [72]. However,
the contribution of NFκB, if any, to platelet activation is
not known. We conclude from this analysis that the female
signaling proteome is characterized by regulatory hubs that
are either negative or neutral for megakaryocyte expansion
or platelet activation. It is important to keep in mind,
however, that all the activation processes represented by the
principal hubs in male platelets are also in female platelets.
They are just relatively reduced in expression.
4.4. The Platelet Literature Is Consistent with Male Platelets
Having Enhanced Hemostatic Function. While the levels of
platelet-speciﬁc signaling proteins are higher in male than
female platelets, it is reasonable to question whether these
diﬀerenceshavefunctionalsigniﬁcance.Forexample,inspite
of diﬀerences in expression levels, there may yet be suﬃ-
c i e n tl e v e l so fd i ﬀerent proteins to drive gender-equivalent
coagulation processes. However, from the limited available
literature, platelets from male human donors do appear to
have enhanced hemostatic activity compared to platelets
from female donors. For example, studies of interactions
between platelets and the subendothelium have indicated
that platelets from males interact more profoundly with
the subendothelium than platelets from female donors [73].
In addition, aspirin treatment of the donors signiﬁcantly
reducestheplatelet-subendotheliuminteractioninmalesbut
not females. Thus the interaction seems to be controlled by
the gender of the platelet donor. In a more recent study with
human umbilical artery segments [74], platelet spreading
and adherence were shown to be signiﬁcantly greater with
platelets from male than female donors. Coincidentally,
bothcollagen-inducedandarachidonicacid-inducedplatelet
aggregation in platelets from male donors are also correlated
with enhanced adherence. Finally, the latter authors reported
that the mean bleeding time was slightly longer in women
than men.
Gender-dependent diﬀerences in platelet function have
also been reported experimentally in diﬀerent systems.
For example, pathologic platelet hyper-reactivity has been
reported in a large study of women with a family history of
premature atherosclerosis [75]. Estrogen itself has dramatic
positive eﬀects on megakaryocytic expansion and platelet
production in humans [76]a n dm i c e[ 77, 78]. In sexually
mature pigs, platelet aggregation and dense body ATP secre-
tion are greater in male than female pigs [79]. We therefore
suggestthatthedominantprocoagulantcharacterofthemale
platelet signaling proteome, which we have demonstrated
here for the ﬁrst time, is consistent with these functional
data. However, the fact is that we cannot, ap r i o r i , know
withcertaintywhetheranyofthesefunctionaldiﬀerencescan
be traced directly to diﬀerences in the respective signaling
proteomes.
5. Conclusion
We conclude that the diﬀerent proteomic signaling sig-
natures for male and female platelets may very likely
provide a candidate biological mechanism for the female
gender gap advantage over males for cardiovascular diseases.
Substantial amounts of work have been published on the
high-abundance platelet proteome [80–82]. However, none
of these studies addressed the issue of gender-speciﬁcity.
Neither could they have, considering the proteomic tech-
nologies employed. Our own investigation of the high
abundance platelet proteome indicates that few examples
of gender dependence would have been found. By contrast,
our data show unambiguously that the gender-diﬀerence is
accessible only in the low-abundance signaling proteome.
Globally,thelow-abundanceproteomeispresentlyaccessible
only through the novel, quantitative and highly sensitive
protein microarray platform described here. Individually,
many of the diﬀerences in protein expression can be vali-
dated by Western blot. Nonetheless, we need to emphasize
that these conclusions are based on platelets from just
16 randomly chosen healthy control humans. Certainly.
additional datasets will be needed to test the constancy
of the speciﬁc protein measurements. We therefore suggest
that the discovery of gender-speciﬁcity for a subset of the
platelet signaling proteome is completely unprecedented,
and adds a fundamentally new candidate mechanism for
gender discrimination in cardiovascular disease.
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